匹维溴胺联合脏连丸治疗肠易激综合症的临床观察

目的: 观察匹维溴胺联合脏连丸治疗肠易激综合症的疗效及安全性。方法: 将200例肠易激综合症患者均分为2组。研究组100例应用匹维溴胺联合脏连丸治疗,对照组应用匹维溴胺治疗,观察两组疗效。参照中药新药临床研究指导原则,观察腹痛、腹胀、腹泻、黏液便等症状及发作频率变化,记录药物不良反应。应用SPSS 16.0 统计学软件,计数资料应用χ²检验,计量资料应用t检验。结果: 治疗后两组临床症状较治疗前均有改善,差异有统计学意义(P<0.05)。研究组有效率为97%,高于对照组的80%,差异具有统计学意义(χ²=5.71,P<0.05)。两组均未发现明显的药物不良反应,肝、肾功能及血常规检查正常。结论: 匹维溴胺联合脏连丸治疗肠易激综合症有较好的临床效果,且安全性较好。

Clinical treatment of combining with Pinaverium bromide and Zanglian pill on patients with irritable bowei syndrome

AIM: To observe the effects and safety of combining with Pinaverium bromide and Zanglian pill on patients with irritable bowei syndrome (IBS).METHODS: 200 IBS patients were randomly divided into two groups(n=100). 100 patients were selected as study group, who were treated by Zanglian pill combined with Pinaverium bromide while the other 100 patients as control group were treated by Pinaverium bromide only.RESULTS: After treatment, all patients showed significant improvements of clinical symptom (P<0.05).The effective power was 97% in study group, was better than that in control group(80%,P<0.05). The two groups were not found significant adverse drug reactions.CONCLUSION: Zanglian pill combined with Pinaverium bromide have more clinic effects for treating IBS.